Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: In ulcerative colitis (UC) patients, Escherichia coli Nissle 1917 (EcN) is equivalent to mesalazine for preventing disease relapse; however, evidence of the ability of EcN to increase health-related quality of life or induce remission remains scarce. We investigated the efficacy of EcN as an add-on therapy for UC. Methods: In this multicentre, double-blind, randomised, placebo-controlled study, a total of 133 UC patients were randomly assigned to receive either EcN or placebo once daily for 8 weeks. Inflammatory bowel disease questionnaire (IBDQ) scores (primary endpoint) and clinical remission and response rates (secondary endpoints) were compared (Clinical trial registration number: NCT04969679). Results: In total, 118 patients (EcN, 58; placebo, 60) completed the study. The number of patients reaching the primary endpoint did not differ between the EcN and placebo groups (30 [51.7%] vs. 31 [51.7%]; per-protocol analysis, p = 1.0; intention- to-treat analysis, p = 0.86). However, significantly fewer patients in the EcN group exhibited a decreased IBDQ score (1 [1.7%] vs. 8 [13.3%]; per-protocol analysis, p = 0.03; intention-to-treat analysis, p = 0.02). Moreover, a significantly higher number of patients in the EcN group displayed clinical response at 4 weeks (23 [39.7%] vs. 13 [21.7%], p = 0.04) and endoscopic remission at 8 weeks (26 [46.4%] vs. 16 [27.1%], p = 0.03). Conclusions: Although the number of patients reaching the primary endpoint did not differ between the EcN and placebo groups, EcN was found to be safe and effective in preventing the exacerbation of IBDQ scores and achieving clinical responses and endoscopic remission in patients with mild-to-moderate UC.
Abstract
Background/Aims: In ulcerative colitis (UC) patients, Escherichia coli Nissle 1917 (EcN) is equivalent to mesalazine for preventing disease relapse; however, evidence of the ability of EcN to increase health-related quality of life or induce remission remains scarce. We investigated the efficacy of EcN as an add-on therapy for UC. Methods: In this multicentre, double-blind, randomised, placebo-controlled study, a total of 133 UC patients were randomly assigned to receive either EcN or placebo once daily for 8 weeks. Inflammatory bowel disease questionnaire (IBDQ) scores (primary endpoint) and clinical remission and response rates (secondary endpoints) were compared (Clinical trial registration number: NCT04969679). Results: In total, 118 patients (EcN, 58; placebo, 60) completed the study. The number of patients reaching the primary endpoint did not differ between the EcN and placebo groups (30 [51.7%] vs. 31 [51.7%]; per-protocol analysis, p = 1.0; intention- to-treat analysis, p = 0.86). However, significantly fewer patients in the EcN group exhibited a decreased IBDQ score (1 [1.7%] vs. 8 [13.3%]; per-protocol analysis, p = 0.03; intention-to-treat analysis, p = 0.02). Moreover, a significantly higher number of patients in the EcN group displayed clinical response at 4 weeks (23 [39.7%] vs. 13 [21.7%], p = 0.04) and endoscopic remission at 8 weeks (26 [46.4%] vs. 16 [27.1%], p = 0.03). Conclusions: Although the number of patients reaching the primary endpoint did not differ between the EcN and placebo groups, EcN was found to be safe and effective in preventing the exacerbation of IBDQ scores and achieving clinical responses and endoscopic remission in patients with mild-to-moderate UC.
참고문헌 (19)
- Sartor RB, "Mechanisms of disease : pathogenesis of Crohn’s disease and ulcerative colitis", Nat Clin Pract Gastroenterol Hepatol, 3, pp.390~407 (2006)
- 조영석, "Multi-session fecal microbiota transplantation using colonoscopy has favorable outcomes for the treatment of steroid-dependent ulcerative colitis", Intestinal research, 17(1), pp.6~8 (2019), 대한장연구학회[DOI]
- Tomohiro Fukuda, "Current new challenges in the management of ulcerative colitis", Intestinal research, 17(1), pp.36~44 (2019), 대한장연구학회[DOI]
- Ajit Sood, "Efficacy of fecal microbiota therapy in steroid dependent ulcerative colitis: a real world intention-to-treat analysis", Intestinal research, 17(1), pp.78~86 (2019), 대한장연구학회[DOI]
- Gallo A, "Modulation of microbiota as treatment for intestinal inflammatory disorders : an uptodate", World J Gastroenterol, 22, pp.7186~7202 (2016)
- Derikx LA, "Probiotics and prebiotics in ulcerative colitis", Best Pract Res Clin Gastroenterol, 30, pp.55~71 (2016)
- Schultz M, "Clinical use of E. coli Nissle 1917 in inflammatory bowel disease", Inflamm Bowel Dis, 14, pp.1012~1018 (2008)
- Schlee M, "Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin", Infect Immun, 75, pp.2399~2407 (2007)
- Losurdo G, "Escherichia coli Nissle 1917 in ulcerative colitis treatment : systematic review and meta-analysis", J Gastrointestin Liver Dis, 24, pp.499~505 (2015)
- 최창환, "Second Korean guidelines for the management of ulcerative colitis", Intestinal research, 15(1), pp.7~37 (2017), 대한장연구학회
- LeBlanc K, "The impact of biological interventions for ulcerative colitis on health-related quality of life", Cochrane Database Syst Rev, 9, pp.CD008655~ (2015)
- Lewis JD, "Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis", Inflamm Bowel Dis, 14, pp.1660~1666 (2008)
- Guyatt G, "A new measure of health status for clinical trials in inflammatory bowel disease", Gastroenterology, 96, pp.804~810 (1989)
- Petersen AM, "Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis : a double-blind randomized placebo controlled clinical trial", J Crohns Colitis, 8, pp.1498~1505 (2014)
- Rembacken BJ, "Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis : a randomised trial", Lancet, 354, pp.635~639 (1999)
- Matthes H, "Clinical trial : probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917(EcN)", BMC Complement Altern Med, 10, pp.13~ (2010)
- Fujimori S, "A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis", Nutrition, 25, pp.520~525 (2009)
- Yasueda A, "The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis", Surg Today, 46, pp.939~949 (2016)
- Gao R, "Gut microbiota alteration after long-term consumption of probiotics in the elderly", Probiotics Antimicrob Proteins, 11, pp.655~666 (2019)